The European Medicines Agency has rebutted a French MP’s accusations that an agency expert had minimised the potential health risks of fenfluramines, marketed by French company Servier as the appetite suppressant Isoméride in the 1990s.
Last month, Gérard Bapt, a French socialist MP, claimed in a letter to the European health commissioner, John Dalli, that a 1994 report by Xavier Kurz, who then worked as a Belgian pharmacovigilance official, had “tended to minimise or contest safety signals” of potential heart risks.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.